Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Grow...(Q7) How did the TAP joint venture perfo...),Health

A7) Income from the TAP joint venture was in line with previous

forecasts. Prevacid sales were $550 million and Lupron sales were

$147 million.

In March, Abbott and Takeda announced an agreement to conclude the

TAP joint venture, evenly splitting the assets. Abbott expects the

transaction to be neutral to 2008 earnings per share and neutral or

better over the next five years. The transaction is expected to

close in the second quarter of 2008.

After the close of the transaction, Abbott will no longer record TAP

joint venture income. Instead, U.S. Lupron sales and costs

associated with the franchise will be included in Abbott's operating

results. Abbott will also record, as other income, the estimated

future cash payments from Takeda of approximately $1.5 billion over

the next five years based on TAP's current and future product

portfolio.

Q8) What are some near-term opportunities from Abbott's pipeline?

A8) Abbott has a number of promising late-stage programs in its

pharmaceutical and medical products pipeline, including:

* HUMIRA

o Psoriasis -- Launched in Europe and the United States in

the first quarter of 2008.

o Juvenile RA -- Received regulatory approval in the first

quarter of 2008.

o Ulcerative colitis -- Currently in Phase III development.

o RA in Japan -- Received approval in April 2008.

* XIENCE V Drug-Eluting Stent (DES) -- Launched outside the

United States, submitted to the U.S. Food and Drug

Administration (FDA) and is currently under regulatory review.

In the fourth-quarter 2007, an FD
'/>"/>